Moderna Inc logo

MRNA - Moderna Inc Share Price

$61.5 6.0  10.7%

Last Trade - 29/05/20

Large Cap
Market Cap £19.32bn
Enterprise Value £18.36bn
Revenue £42.6m
Position in Universe 370th / 6364
Unlock MRNA Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Moderna Inc revenues decreased 48% to $8.4M. Net loss decreased 6% to $124.2M. Revenues reflect Collaboration Arrangement decrease of 76% to $3.2M. Lower net loss reflects Research and development decrease of 14% to $103.1M (expense), General and administrative decrease of 19% to $15.7M (expense), Other income (expense), net increase from $395K (expense) to $191K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MRNA Revenue Unlock MRNA Revenue

Net Income

MRNA Net Income Unlock MRNA Revenue

Normalised EPS

MRNA Normalised EPS Unlock MRNA Revenue

PE Ratio Range

MRNA PE Ratio Range Unlock MRNA Revenue

Dividend Yield Range

MRNA Dividend Yield Range Unlock MRNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MRNA EPS Forecasts Unlock MRNA Revenue
Profile Summary

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated July 22, 2016
Public Since December 7, 2018
No. of Shareholders: 149
No. of Employees: 830
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 387,702,805
Free Float (0.0%)
Eligible for
MRNA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MRNA
Upcoming Events for MRNA
Tuesday 2nd June, 2020
Moderna Inc Virtual Science Day
Wednesday 3rd June, 2020
Moderna Inc at Jefferies Healthcare Conference (Virtual)
Thursday 11th June, 2020
Moderna Inc at Goldman Sachs Global Healthcare Conference (Virtual)
Wednesday 17th June, 2020
Moderna Inc Secondary Public Offering Lockup Expiration
Wednesday 5th August, 2020 Estimate
Q2 2020 Moderna Inc Earnings Release
Thursday 17th September, 2020
Moderna Inc Corporate Analyst Meeting
Wednesday 4th November, 2020 Estimate
Q3 2020 Moderna Inc Earnings Release
Frequently Asked Questions for Moderna Inc
What is the Moderna Inc share price?

As of 29/05/20, shares in Moderna Inc are trading at $61.5, giving the company a market capitalisation of £19.32bn. This share price information is delayed by 15 minutes.

How has the Moderna Inc share price performed this year?

Shares in Moderna Inc are currently trading at $61.5 and the price has moved by 0.186k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Moderna Inc price has moved by 0.160k% over the past year.

What are the analyst and broker recommendations for Moderna Inc?

Of the analysts with advisory recommendations for Moderna Inc, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Moderna Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Moderna Inc next release its financial results?

Moderna Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Moderna Inc dividend yield?

Moderna Inc does not currently pay a dividend.

Does Moderna Inc pay a dividend?

Moderna Inc does not currently pay a dividend.

When does Moderna Inc next pay dividends?

Moderna Inc does not currently pay a dividend.

How do I buy Moderna Inc shares?

To buy shares in Moderna Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Moderna Inc?

Shares in Moderna Inc are currently trading at $61.5, giving the company a market capitalisation of £19.32bn.

Where are Moderna Inc shares listed? Where are Moderna Inc shares listed?

Here are the trading details for Moderna Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: MRNA
What kind of share is Moderna Inc?

Based on an overall assessment of its quality, value and momentum, Moderna Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Moderna Inc share price forecast 2020?

Shares in Moderna Inc are currently priced at $61.5. At that level they are trading at 46.94% premium to the analyst consensus target price of 0.00.

Analysts covering Moderna Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.496 for the next financial year.

How can I tell whether the Moderna Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moderna Inc. Over the past six months, the relative strength of its shares against the market has been 0.210k%. At the current price of $61.5, shares in Moderna Inc are trading at 0.138k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Moderna Inc PE Ratio?

We were not able to find PE ratio data for Moderna Inc.

Who are the key directors of Moderna Inc?

Moderna Inc's management team is headed by:

Noubar Afeyan - NEC
Stephen Hoge - PRE
Stephane Bancel - CEO
Lorence Kim - CFO
Juan Andres - CTO
Lori Henderson - GCN
Marcello Damiani - OTH
Tal Zvi Zaks - OTH
Stephen Berenson - NID
Robert Langer - NID
Elizabeth Nabel - NID
Israel Ruiz - NID
Francois Nader - NID
Tracey Franklin - CHO
Who are the major shareholders of Moderna Inc?

Here are the top five shareholders of Moderna Inc based on the size of their shareholding:

Flagship Ventures Venture Capital
Percentage owned: 13.12% (50.9m shares)
Zeneca Inc Corporation
Percentage owned: 6.58% (25.5m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 6.39% (24.8m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.31% (20.6m shares)
Springer (Timothy) Individual Investor
Percentage owned: 3.36% (13.0m shares)
Similar to MRNA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.